The firm's pipeline of clinical-stage drug candidates includes Pracinostat, an oral HDAC inhibitor partnered with Helsinn; ME-401, a highly differentiated, oral PI3K delta inhibitor; Voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor.